National program for Clinical Treatment Research in the Specialist Health Service (KLINBEFORSK)

  • Project: PANORAMIC Norway - Interventions against long COVID in Norway (2022-2025)
  • Project Owner: Haukeland University Hospital
  • Total Budget: 20 million NOK
  • Research Group Funding: 12.9 million NOK

EU Innovative Health Initiative (IHI)

  • Project: Inno4Vac - Innovations to accelerate vaccine development and manufacture (2021-2026)
  • Project Owner: European Vaccine Initiative (EVI)
  • Total Budget: €18.6 million
  • Research Group Funding: €752,594 (Work Package lead for development of an improved influenza human challenge model)

Horizon 2020 EU's research and innovation funding programme (H2020)

  • Project: VACCELERATE - European Corona Vaccine Trial Accelerator Platform (2021-2025)
  • Project Owner: University of Cologne, Germany
  • Total Budget: €12 million
  • Research Group Funding: €661,033 (National Coordinator and Work Package leader)

The Research Council of Norway (RCN), TMF, Western Norway Regional Health authority (Helse Vest RHF)

  • Project: COVID-19 in healthcare workers and the general population in Western Norway (2020-2024)
  • Project Owner: University of Bergen, Haukeland University Hospital
  • Research Group Funding: 11.2 million NOK

Trond Mohn Foundation

  • Project: COVID-19 infection in healthcare workers and the general population (2020-2022)

NORCE Research

  • Project: MONCOVID-19: Technologies for Monitoring COVID-19 Epidemiological Development (2020-2022)
  • Project Link / Website: MONCOVID-19 Project

Helse Vest

  • Project: Research into COVID-19 Infection in Bergen: The Clinical and Immune Response in Healthcare Workers and the General Population (2020-2021)
  • Project Number: F-11628

EU Innovative Medicines Initiative (IMI)

  • Project: FLUCOP - Standardisation and development of assays for assessment of influenza vaccine correlates of protection (2015-2020)
  • Project Owner: SANOFI PASTEUR SA
  • Total Budget: €13.85 million
  • Research Group Funding: €697,000

EU Nanomedicines (2017-2021)

  • Project: Design of Human Influenza vaccines using multifunctional micelles harnessing innate immunity
  • Partners: Centre National de la Recherche Scientifique (CNRS), France; Fundació Clínic per la Recerca Biomèdica (FCRB) - Hospital Clinic de Barcelona (HCB), Spain; ADJUVATIS, France; Commissariat à l’Energie Atomique IDMIT, France; University of Bergen

RCN Norwegian Research School in Infection Biology and Antimicrobials (IBA) (2016-2020)

  • Partners: University of Oslo, University of Tromsø, Norwegian University of Life Sciences, Norwegian University of Science and Technology, University of Bergen, Faculty of Medicine Umeå University, Sweden, University of Copenhagen, Denmark
  • Total budget: 23.8 million kroner

K.G. Jebsen Centre for Influenza Vaccine Research (2013-2019)

  • Partners: University of Oslo, Oslo University Hospital, The Norwegian Institute of Public Health, University of Bergen
  • Total budget: 20 million kr

EU FP7 Univax (2013-2018)

  • Project: A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines
  • Partners: Switzerland, France, Russian Federation, Germany, Czech Republic, UK, Norway
  • Total budget: €6 million
  • Project Link / Website: EU FP7 Univax Project

RCN Globvac (2013-2017)

  • Project: Improved childhood vaccination and preparedness against seasonal and pandemic influenza: prospects for cellular immunity
  • Partners: Norway (The Norwegian Institute of Public Health, University of Bergen), USA, Hungary, Bangladesh, and Ethiopia

RCN Biobank (2013-2017)

  • Project: Perinatal outcomes and children’s health after prenatal exposure to influenza and influenza vaccination
  • Partners: Norway (The Norwegian Institute of Public Health, University of Bergen), USA (Columbia University, La Jolla Institute of Allergy and Immunology)

Helse Vest Influenza A(H7) Studies (2014-2016)

  • Partners: University of Bergen, Health Protection England, UK; University of Oxford, UK; Mount Sinai USA

RCN Globvac (2008-2012)

  • Project: The immunogenicity & protective efficacy of plant-derived influenza H5N1 vaccine in preclinical models
  • Partners: UK, Germany, USA, and Norway

EU FP7 NASPANVAC (2008-2012)

  • Project: Intranasal pandemic influenza vaccine
  • Partners: UK, Ireland, Italy, and Norway

EU FP6 Panfluvac (2007-2011)

  • Project: Efficacious vaccine formulation system for prophylactic control of influenza pandemics
  • Partners: Switzerland, UK, Germany, Italy, and Norway

EU FP5 FLUPAN (2001-2006)

  • Project: Preparing for an influenza pandemic
  • Partners: UK, France, Italy, and Norway

EU FP 4 (1996-1999)

  • Project: Genetic and immunological safety of DNA vaccines
  • Partners: UK, Ireland, Spain, and Norway